<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thirty-six <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> patients received every 2 weeks, as first- (17) or second-line (19) treatment a combined chronotherapy with <z:chebi fb="9" ids="27656">CPT</z:chebi>-11 (infused at day 1 from 2 to 8 a.m.; peak at 5 a.m.), given with 5FU (700 mg/m(2) per day; days 2-5) and folinic acid (300mg/m(2) per day; days 2-5) both infused from 10 p.m. to 10 a.m. with a peak at 4 a.m., and <z:chebi fb="2" ids="31355">carboplatin</z:chebi> (40mg/m(2) per day; days 2-5; infused from 10 a.m. to 10 p.m.; peak at 4 p.m.) </plain></SENT>
<SENT sid="1" pm="."><plain>The doses of CPT11 could be easily pushed from 120 to 180mg/m(2) in successive cohorts in the phase I part of the study (11 cases) </plain></SENT>
<SENT sid="2" pm="."><plain>Twenty-five patients were then treated in the phase II of the trial </plain></SENT>
<SENT sid="3" pm="."><plain>The overall toxicity was mild leading to dose-reductions in only 11-13% courses </plain></SENT>
<SENT sid="4" pm="."><plain>The tumoral activity was interesting with 81% responses and 94% <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> control </plain></SENT>
<SENT sid="5" pm="."><plain>Also prolonged survivals were recorded with 8.8months of progression free and 15.6months overall survivals </plain></SENT>
<SENT sid="6" pm="."><plain>More prolonged survivals were observed in chemotherapy naive patients </plain></SENT>
<SENT sid="7" pm="."><plain>Seven patients (19%) could be reoperated from their <z:e sem="disease" ids="C0543478" disease_type="Neoplastic Process" abbrv="">residual disease</z:e> </plain></SENT>
</text></document>